<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="896">
  <stage>Registered</stage>
  <submitdate>27/09/2005</submitdate>
  <approvaldate>27/09/2005</approvaldate>
  <nctid>NCT00227500</nctid>
  <trial_identification>
    <studytitle>Pravastatin for Hyperlipidaemia in HIV.</studytitle>
    <scientifictitle>A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PRAVA / RO1 HL65953-01</secondaryid>
    <secondaryid>PRAVA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <healthcondition>Lipid Metabolism</healthcondition>
    <healthcondition>Glucose Metabolism</healthcondition>
    <healthcondition>Metabolic Abnormality</healthcondition>
    <healthcondition>Lipodystrophy</healthcondition>
    <healthcondition>Cardiovascular Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Pravastatin

Treatment: drugs: Pravastatin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Between-group difference in time weighted change from baseline in fasting serum total cholesterol</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Includes: between-group difference in time weighted change: from wk 4 in fasting serum total cholesterol as well as from baseline in HDL-cholesterol and triglycerides; in total and regional body fat; in endothelial function</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provide written informed consent to participate in the trial

          -  HIV-1 sero-positive

          -  Male/female &gt;18 years age

          -  Currently receiving HIV protease inhibitor therapy for &gt; 12 weeks and unlikely to
             require change in existing regimen during the 16 week study period

          -  Fasting cholesterol &gt; 6.5 mmol/L (mean of 2 samples collected &gt; 3 days apart)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any condition which may interfere with ability to comply with study

          -  Gastrointestinal disorder which may affect drug absorption

          -  Hypertension or congestive cardiac failure

          -  Lactic acidemia (serum lactate level &gt;2.2 mmol/L)

          -  Any serious medical condition which may compromise the patients safety, including
             pancreatitis or hepatitis within past 6 months

          -  Active AIDS defining conditions

          -  Concurrent therapy with any other lipid lowering agents, oral hypoglycaemics, anabolic
             steroids or insulin</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St. Vincents Hospital - Sydney</hospital>
    <postcode>2010 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The University of New South Wales</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Heart, Lung, and Blood Institute (NHLBI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Garvan Institute of Medical Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>St Vincent's Hospital, Sydney</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is a randomised, placebo-controlled study of the effect of treatment with the
      HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated
      patients with high serum cholesterol. We hypothesise that pravastatin will result in greater
      reductions in cholesterol than placebo when used in conjunction with appropriate dietary
      advice.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00227500</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew D Carr, MD</name>
      <address>National Centre in HIV Epidemiology and Clinical Research.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>